Neutron encoded activity based probes
基于中子编码活动的探针
基本信息
- 批准号:10624458
- 负责人:
- 金额:$ 42.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAmino AcidsAreaBar CodesBasic ScienceBindingBiochemical PathwayBiologicalCatalogsCell LineCellsChemicalsChromatinClinicalCollectionData AnalysesDefectDetectionDevelopmentDiseaseDrug DesignDrug TargetingElementsEnzymesFrustrationGenerationsHistone AcetylationHistone DeacetylaseHistone Deacetylase InhibitorIsotopesLibrariesLifeLigationMalignant NeoplasmsMass Spectrum AnalysisMeasuresMetabolicMethodologyMethodsMolecular Mechanisms of ActionNeutronsNuclearPatternPharmaceutical PreparationsPharmacologyPhotoaffinity LabelsPhysiologicalPiperazinesProcessProteinsProteomeReactionReagentRegulationResistanceResolutionSamplingSiteSpecificityStatistical Data InterpretationStructureSupport GroupsSystemSystems AnalysisTechnologyTestingToxic effectTreatment EfficacyWorkblindcandidate selectionclinical applicationcombinatorialdesigndrug candidatedrug developmentdrug discoverydrug-like compoundenantiomerhigh throughput screeningin vivoinhibitorinnovationnovelnovel drug classpharmacologicscaffoldside effectsmall moleculesmall molecule inhibitorsuccess
项目摘要
Drugs are designed to modulate the function of a critical protein involved in a disease; however, almost all small
molecules have off-targets which can mitigate or altogether terminate their therapeutic efficacy. Unfortunately,
there are no general methods that can identify all the protein targets that a drug binds to in an unbiased manner.
For example, Histone Deacetylase Inhibitors (HDACIs) show promising clinical activity in many diseases;
however, they are generally of low to moderate specificity and may act in part through, or be hindered by,
uncharacterized off-target interactions. We propose a strategy that will allow for rapid and deep
pharmacological profiling of early drug candidates that 1) identifies protein targets with extraordinary
confidence, 2) localizes the precise site of interaction often with amino acid residue specificity, 3) is robust against
metabolic alterations, 4) distinguishes the pharmacology of metabolites, 5) quantitates differences in
pharmacological activity between cellular contexts. With this approach we will quantitate all interactions that
each inhibitor has with proteins in a living cell. An neutron-encoded ‘bar code’ is added to activity-based
probes during a click capture and release that allows us to blindly trace the drug in a nominal mass independent
manner and simultaneously introduce quantitation channels. The barcodes are revealed in the isotopic fine
structure by high resolution mass spectrometry yet do not compromise sensitivity at lower resolution
fragmentation spectra. The neutron bar code is implemented by moving neutrons between elements and results
in a prescribed pattern of relativistic nuclear mass defects embedded in the framework of a small molecule. With
this method we can confidently retrieve drug-protein reaction products from in vivo systems regardless of
metabolic alterations to the HDAC inhibitors, measure a pharmacological profile and determine molecular
mechanism of action. Our central hypothesis is that neutron encoded activity based probe pharmacological
profiling combined with innovative fragment-based discovery to generate selective HDACIs will enable the
generation of a library of highly characterized and diversely selective HDACI probes. This will be realized through
three specific aims: in aim 1 we will employ a novel and systematically diverse group of sp3-enriched fragments
to generate HDACIs that sample the rim region of HDACs leading to highly selective interactions. In aim 2 we
will measure the pharmacological profile of our novel HDACi’s and their effect on histone acetylation. In aim 3,
we will develop a multiplexed barcoding system which to enable higher detection and resolution of drug targets
over the entire proteome. This overcomes many challenges universal to early stage drug development
efforts that have frustrated the development of specific HDAC inhibitors in particular. Although HDACIs
will be the general focus of this proposal our method is general for drug development in any area.
药物被设计用来调节一种与疾病有关的关键蛋白质的功能;然而,几乎所有小的
分子具有非靶点,可以减轻或完全终止其治疗效果。不幸的是,
没有通用的方法可以以公正的方式识别药物结合的所有蛋白质靶标。
例如,组蛋白脱乙酰酶抑制剂(HDACIs)在许多疾病中显示出良好的临床活性;
然而,它们通常具有低到中等的特异性,可能部分通过或受到以下因素的阻碍:
未描述的脱离目标的相互作用。我们提出了一项战略,将允许快速和深入的
早期候选药物的药理学图谱:1)识别具有特殊功能的蛋白质靶点
置信度,2)通常用氨基酸残基专一性来定位相互作用的精确位置,3)对
代谢改变,4)区分代谢物的药理学,5)量化
细胞环境之间的药理活性。使用此方法,我们将量化所有
每一种抑制物都与活细胞中的蛋白质发生了作用。一个中子编码的条形码被添加到基于活动的
点击捕获和释放期间的探针,允许我们以名义质量无关的方式盲目追踪药物
同时引入量化渠道。条形码在同位素罚款中显露出来
结构,但不影响较低分辨率下的灵敏度
碎裂光谱。中子条形码是通过在元素和结果之间移动中子来实现的
在小分子框架内嵌入的相对论核质量缺陷的规定模式中。使用
这种方法我们可以自信地从体内系统中检索药物-蛋白质反应产物,而不需要考虑
HDAC抑制剂的代谢变化,测量药理学特征并确定分子
作用机制。我们的中心假设是,基于中子编码活性的探针药理学
分析与创新的基于片段的发现相结合以生成选择性HDACI将使
产生具有高度特征性和不同选择性的HDACi探针库。这将通过以下方式实现
三个具体目标:在目标1中,我们将使用一组新颖的和系统多样化的SP3富含片段
以产生对HDAC的边缘区域进行采样的HDACI,从而导致高度选择性的相互作用。在《目标2》中,我们
将测量我们的新型HDACi的药理学特征以及它们对组蛋白乙酰化的影响。在《目标3》中,
我们将开发一种多路复用条形码系统,以实现对毒品目标的更高检测和分辨率
整个蛋白质组。这克服了早期药物开发普遍存在的许多挑战
尤其是阻碍了特定的HDAC抑制剂的开发的努力。尽管HDACI
将是这项建议的总体重点,我们的方法对于任何领域的药物开发都是通用的。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Expeditious Extraction of Histones from Limited Cells or Tissue Samples and Quantitative Top-Down Proteomic Analysis.
- DOI:10.1002/cpz1.26
- 发表时间:2021-03
- 期刊:
- 影响因子:0
- 作者:Holt MV;Wang T;Young NL
- 通讯作者:Young NL
Mechanistic insights into KDM4A driven genomic instability.
- DOI:10.1042/bst20191219
- 发表时间:2021-02-26
- 期刊:
- 影响因子:3.9
- 作者:Young NL;Dere R
- 通讯作者:Dere R
Gene therapy using Aβ variants for amyloid reduction.
使用 Aβ 变体进行淀粉样蛋白减少的基因治疗。
- DOI:10.1016/j.ymthe.2021.02.026
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Park,Kyung-Won;Wood,CalebA;Li,Jun;Taylor,BethanyC;Oh,SaeWoong;Young,NicolasL;Jankowsky,JoannaL
- 通讯作者:Jankowsky,JoannaL
A Concise Synthetic Method for Constructing 3-Substituted Piperazine-2-Acetic Acid Esters from 1,2-Diamines.
- DOI:10.3390/molecules27113419
- 发表时间:2022-05-25
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Chemical Catalysis Guides Structural Identification for the Major In Vivo Metabolite of the BET Inhibitor JQ1.
- DOI:10.1021/acsmedchemlett.3c00464
- 发表时间:2024-01-11
- 期刊:
- 影响因子:4.2
- 作者:Holmes, Secondra;Jain, Prashi;Rodriguez, Kenneth Guzman;Williams, Jade;Yu, Zhifeng;Cerda-Smith, Christian;Samuel, Errol L. G.;Campbell, James;Hakenjos, John Michael;Monsivais, Diana;Li, Feng;Chamakuri, Srinivas;Matzuk, Martin M.;Santini, Conrad;Mackenzie, Kevin R.;Young, Damian W.
- 通讯作者:Young, Damian W.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Damian Winston Young其他文献
Damian Winston Young的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Damian Winston Young', 18)}}的其他基金
DNA-Encoded Chemistry Technology (DEC-Tec) Core
DNA 编码化学技术 (DEC-Tec) 核心
- 批准号:
10164825 - 财政年份:2017
- 资助金额:
$ 42.95万 - 项目类别:
Coordinating CMLD methodology with the build/couple/pair strategy to yield comple
将 CMLD 方法与构建/耦合/配对策略相协调,以生成完整的
- 批准号:
7696753 - 财政年份:2008
- 资助金额:
$ 42.95万 - 项目类别:
Coordinating CMLD methodology with the build/couple/pair strategy to yield comple
将 CMLD 方法与构建/耦合/配对策略相协调,以生成完整的
- 批准号:
7897836 - 财政年份:
- 资助金额:
$ 42.95万 - 项目类别:
Coordinating CMLD methodology with the build/couple/pair strategy to yield comple
将 CMLD 方法与构建/耦合/配对策略相协调,以生成完整的
- 批准号:
7932232 - 财政年份:
- 资助金额:
$ 42.95万 - 项目类别:
Discovery of UHRF1 inhibitors in the treatment of hepatocellular carcinoma
UHRF1抑制剂治疗肝细胞癌的发现
- 批准号:
9789211 - 财政年份:
- 资助金额:
$ 42.95万 - 项目类别:
Coordinating CMLD methodology with the build/couple/pair strategy to yield comple
将 CMLD 方法与构建/耦合/配对策略相协调,以生成完整的
- 批准号:
8144393 - 财政年份:
- 资助金额:
$ 42.95万 - 项目类别:
Discovery of UHRF1 inhibitors in the treatment of hepatocellular carcinoma
UHRF1抑制剂治疗肝细胞癌的发现
- 批准号:
9789847 - 财政年份:
- 资助金额:
$ 42.95万 - 项目类别:
Discovery of UHRF1 inhibitors in the treatment of hepatocellular carcinoma
UHRF1抑制剂治疗肝细胞癌的发现
- 批准号:
9635376 - 财政年份:
- 资助金额:
$ 42.95万 - 项目类别:
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 42.95万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 42.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 42.95万 - 项目类别:














{{item.name}}会员




